- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.05. | Galera Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 14.05. | Galera Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 19.04. | Obsidian, Galera Therapeutics Merger Comes With $350M Infusion for Cancer Drug Trials | 2 | MedCity News | ||
| GALERA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 15.04. | Obsidian, Galera Therapeutics to advance cell therapy following reverse merger | 4 | BioPharma Dive | ||
| 15.04. | Obsidian Therapeutics To Merge With Galera Therapeutics In Reverse Merger | - | RTTNews | ||
| 15.04. | Obsidian Therapeutics to go public via Galera Therapeutics merger | 2 | Investing.com | ||
| 15.04. | Fusion mit Galera Therapeutics: Obsidian Therapeutics strebt Börsengang an | 3 | Investing.com Deutsch | ||
| 15.04. | RTW Biotech Opp. - Obsidian Therapeutics reverse merger with Galera Therapeutics | - | RNS | ||
| 14.04. | Galera Therapeutics und Obsidian kündigen Fusion und 350-Millionen-Dollar-Finanzierung an | 2 | Investing.com Deutsch | ||
| 14.04. | Galera Therapeutics to merge with Obsidian in $350M deal | 2 | Investing.com | ||
| 14.04. | Cell therapy biotech Obsidian leverages Galera Therapeutics reverse merger to go public | 1 | FierceBiotech | ||
| 14.04. | Fusion von Galera Therapeutics und Obsidian Therapeutics: Neues Biotech-Unternehmen sichert sich 350 Millionen US-Dollar | 1 | Investing.com Deutsch | ||
| 14.04. | Obsidian Therapeutics, Inc. and Galera Therapeutics, Inc. Announce Merger Agreement and $350 Million Concurrent Private Placement | 184 | Business Wire | • Combined company to operate as Obsidian Therapeutics, Inc. and to advance Obsidian's pipeline of novel engineered TIL cell therapies for the treatment of patients with solid tumors.
• Obsidian's... ► Artikel lesen | |
| 14.04. | Galera Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.04. | Galera Therapeutics bündelt jährliche Hauptversammlungen für 2025 und 2026 und setzt Termin für Mai fest | 4 | Investing.com Deutsch | ||
| 03.04. | Galera Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.03. | Galera Therapeutics, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 12.02. | Galera Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 22.10.25 | Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million | 1.044 | GlobeNewswire (Europe) | Galera has entered into an Asset Purchase Agreement with Toronto-based Biossil for Galera's dismutase mimetics portfolio, including all avasopasem and rucosopasem formulations and indications. The... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 44,705 | -0,60 % | CRISPR Therapeutics AG (CRSP): One of The most Shorted Mid Cap Stocks to Buy on Robust Gene Editing Pipeline | ||
| NOVOCURE | 15,175 | +11,05 % | NovoCure Ltd - 8-K, Current Report | ||
| SPERO THERAPEUTICS | 2,382 | -2,85 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update | Spero announced the resubmission of tebipenem HBr New Drug Application (NDA) to the FDA for complicated urinary tract infections (cUTI), including pyelonephritis in December 2025In February, Spero's... ► Artikel lesen | |
| PRECISION BIOSCIENCES | 5,490 | -2,66 % | Precision BioSciences, Inc.: Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026 | Late-breaking poster presentation to highlight new biopsy data demonstrating elimination and inactivation of cccDNA from the ongoing Phase 1 ELIMINATE-B trial in chronic hepatitis B
Precision... ► Artikel lesen | |
| BOLT BIOTHERAPEUTICS | 5,820 | -100,00 % | Bolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected in 3Q 2026 Cash balance of $23.9 million as of March 31, 2026 anticipated to fund... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 254,00 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Vormatrigine Program Update | POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 35,590 | 0,00 % | Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.Transaction includes sevasemten, a late-stage investigational treatment for... ► Artikel lesen | |
| JADE BIOSCIENCES | 16,940 | 0,00 % | Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy | ~70% IgA reductions sustained at 12 weeks after a single dose of JADE101>70% IgA reductions projected at steady state with a single subcutaneous maintenance injection every 12 weeksIgA-lowering effect... ► Artikel lesen | |
| QIAGEN | 31,920 | -2,18 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Qiagen mit einem Kursziel von 43 US-Dollar auf "Buy" belassen. Das Feedback aus Gesprächen mit etlichen US-Laborexperten deute darauf hin, dass... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 86,86 | -0,07 % | Weekly Buzz: AstraZeneca, JNJ Get FDA Nod; Eli Lilly To Acquire Curevo; APGE Advances Zumilokibart | NEW BRUNSWICK (dpa-AFX) - This week in the biotech space, there were regulatory approvals across the U.S. and Europe, collaborations, acquisitions, and positive data readouts spanning multiple... ► Artikel lesen | |
| ADMA BIOLOGICS | 7,970 | 0,00 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
| SUMMIT THERAPEUTICS | 14,755 | -0,10 % | All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy | ||
| ERASCA | 11,970 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,315 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 23,720 | +0,13 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing | - Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met - - $500 million committed... ► Artikel lesen |
Das Unternehmen GALERA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GALERA THERAPEUTICS INC finden Sie auf Wallstreet Online.